The company's patented technology harnesses the antimicrobial activity of nitric oxide, providing a unique approach to combatting infectious bacteria and viruses. Their inhalable treatments target antibiotic-resistant pathogens in patients with cystic fibrosis and other respiratory diseases, with promising results against anthrax in preclinical studies. Vast Therapeutics aims to redefine broad-spectrum antimicrobial capability and improve the lives of those suffering from severe respiratory conditions.